OMNIAB INC (OABI)
US68218J1034 - Common Stock
Overall OABI gets a fundamental rating of 4 out of 10. We evaluated OABI against 58 industry peers in the Life Sciences Tools & Services industry. No worries on liquidiy or solvency for OABI as it has an excellent financial health rating, but there are worries on the profitability. OABI is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year OABI has reported negative net income.
In the past year OABI had a positive cash flow from operations.
In the past 5 years OABI always reported negative net income.
The reported operating cash flow has been mixed in the past 5 years: OABI reported negative operating cash flow in multiple years.
1.2 Ratios
Looking at the Return On Assets, with a value of -13.49%, OABI is in line with its industry, outperforming 41.38% of the companies in the same industry.
With a Return On Equity value of -16.09%, OABI perfoms like the industry average, outperforming 50.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -13.49% | ||
| ROE | -16.09% | ||
| ROIC | N/A |
ROA(3y)-9.22%
ROA(5y)N/A
ROE(3y)-11.39%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
OABI does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
OABI does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, OABI has more shares outstanding
OABI has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
OABI has an Altman-Z score of 4.72. This indicates that OABI is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of OABI (4.72) is better than 70.69% of its industry peers.
There is no outstanding debt for OABI. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 4.72 |
ROIC/WACCN/A
WACC12.37%
2.3 Liquidity
OABI has a Current Ratio of 4.11. This indicates that OABI is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of OABI (4.11) is better than 63.79% of its industry peers.
OABI has a Quick Ratio of 4.11. This indicates that OABI is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 4.11, OABI is in the better half of the industry, outperforming 67.24% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.11 | ||
| Quick Ratio | 4.11 |
3. Growth
3.1 Past
The earnings per share for OABI have decreased strongly by -167.26% in the last year.
Looking at the last year, OABI shows a very negative growth in Revenue. The Revenue has decreased by -42.17% in the last year.
OABI shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 13.66% yearly.
EPS 1Y (TTM)-167.26%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-137.5%
Revenue 1Y (TTM)-42.17%
Revenue growth 3Y13.66%
Revenue growth 5YN/A
Revenue growth Q2Q-77.53%
3.2 Future
The Earnings Per Share is expected to grow by 9.80% on average over the next years. This is quite good.
OABI is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 20.59% yearly.
EPS Next Y-12.85%
EPS Next 2Y12.94%
EPS Next 3Y16.86%
EPS Next 5Y9.8%
Revenue Next Year-13.73%
Revenue Next 2Y24.54%
Revenue Next 3Y27.94%
Revenue Next 5Y20.59%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for OABI. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for OABI. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
OABI's Price/Free Cash Flow is on the same level as the industry average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 731.56 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
OABI's earnings are expected to grow with 16.86% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y12.94%
EPS Next 3Y16.86%
5. Dividend
5.1 Amount
No dividends for OABI!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
OMNIAB INC
NASDAQ:OABI (5/20/2024, 3:30:02 PM)
After market: 4.39 0 (0%)4.39
-0.06 (-1.35%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap514.29M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -13.49% | ||
| ROE | -16.09% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.09
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 4.11 | ||
| Quick Ratio | 4.11 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-167.26%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-12.85%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-42.17%
Revenue growth 3Y13.66%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y